Stifel lowered the firm’s price target on Apellis (APLS) to $75 from $84 and keeps a Buy rating on the shares. Feeling headwinds from competitive forces, the company reported Q3 revenues of $196.8M versus consensus at $200M, with Syfovre growing 7% year-over-year but down sequentially on higher G-N and ceding more share to Izervay after its permanent J-Code issuance in April. While Stifel continues to believe there is meaningful unlocked long-term value in both opportunities, it says Apellis has turned into a quarter-to-quarter execution story requiring investor patience.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis reports Q3 EPS (46c), consensus (30c)
- Apellis expects cash to be sufficient to fund expenses to positive cash flow
- Apellis Pharmaceuticals (APLS) Q3 Earnings Cheat Sheet
- Apellis, Sobi announced results from Phase 3 VALIANT study
- Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls